Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBV Technologies (Nasdaq: DBVT) will present additional data from the positive VITESSE Phase 3 study of the VIASKIN Peanut Patch in children ages 4–7 at the AAAAI 2026 Annual Meeting in Philadelphia, Feb 27–Mar 2, 2026.
An oral abstract presentation is scheduled for Feb 28, 2:15–2:25pm ET, with a product theater on Feb 28, 10:00–10:30am ET featuring panelists discussing epicutaneous immunotherapy (EPIT) and early intervention. DBV will also exhibit at booth #1527.
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit in New York on February 12, 2026 at 2:30pm ET. A live webcast will be available and a replay will remain on the company site for 90 days.
Investors can access the live webcast via the company’s Events page and view the replay through the investor website.
DBVT (NYSE Euronext Paris) disclosed its total shares and voting rights as of January 31, 2026 under Article 223-16 of the AMF General Regulations.
The company reported 274,852,082 total shares and a gross total of 274,852,082 voting rights, with a net total of 274,792,237 voting rights (excluding shares without voting rights).
DBV Technologies (NASDAQ:DBVT) announced €166.7 million of gross proceeds from the full exercise of ABSA Warrants and BS Warrants issued in its March 2025 financing, resulting in issuance of 59,657,507 new shares and 71,005,656 second pre-funded warrants.
Proceeds, together with existing cash, are intended to fund working capital, preparation/submission of a potential BLA and launch readiness for VIASKIN Peanut in children 4–7 in the U.S., if approved. The company estimates these funds support operations for at least 12 months and sees no substantial doubt about going concern as of the press release date.
DBVT (NYSE Euronext Paris) reports the total number of shares and voting rights as of December 31, 2025. The company confirms 235,670,864 total shares and a total gross of voting rights: 235,670,864. The total net of voting rights (excluding shares without voting rights) is 235,596,284. This document supersedes the prior publication of January 5, 2026 to reflect earlier exercises of employee stock plan instruments and warrants from a previous financing.
DBV Technologies (Nasdaq: DBVT / Euronext: DBV) published its half-year report on the liquidity contract maintained with ODDO BHF, covering July 1, 2025 to December 31, 2025 and the contract inception on July 1, 2018.
As of December 31, 2025 the liquidity account held 74,580 shares and €527,891.63. At implementation on July 1, 2018 the account held 41,159 shares and €432,367.25. From Jul 1–Dec 31, 2025 the contract executed 1,658 buys and 1,867 sales, with traded volumes of 1,496,975 shares (€3,548,323.07) on purchases and 1,632,464 shares (€3,904,915.92) on sales.
DBVT (NYSE Euronext Paris, ISIN: FR0010417345) announced the total number of shares and voting rights as of December 31, 2025 in accordance with Article 223-16 of the AMF General Regulations.
The company reported a total number of shares of 232,207,589, a total gross of voting rights of 232,207,589, and a total net of voting rights of 232,133,009 (net excludes shares without voting rights). A PDF attachment is available for the detailed statement.
DBV Technologies (Nasdaq:DBVT) announced positive topline Phase 3 VITESSE results for the VIASKIN Peanut patch in children aged 4–7. The trial met its primary endpoint: 46.6% responder rate on active vs 14.8% on placebo (difference 31.8%; 95% CI 24.5–39.0%; lower bound >15%; p=1x10-17). VITESSE enrolled 654 children (438 active, 216 placebo). Safety was consistent with prior studies: no treatment-related serious adverse events, 0.5% treatment-related anaphylaxis (n=2), discontinuations 3.2% active vs 0.5% placebo, and compliance 96.2%. A U.S. BLA submission in H1 2026 is on track. Positive topline results accelerate exercise of warrants, now exercisable through Jan 15, 2026.
Company (NYSE:DBVT) reports the total number of shares and voting rights as of November 30, 2025 under Article 223-16 of the AMF General Regulations.
As of 11/30/2025 the total number of shares is 200,777,718. The total gross voting rights equals 200,777,718 and the total net voting rights is 200,667,869 (net total excludes shares without voting rights). ISIN: FR0010417345.
DBV Technologies (NASDAQ:DBVT) announced completion of the last patient visit in the VITESSE Phase 3 trial of the VIASKIN® Peanut patch in peanut-allergic children aged 4–7 years. The double-blind, placebo-controlled treatment phase is complete and the company remains on track to report topline data in Q4 2025.
The 12-month study enrolled 654 subjects randomized 2:1 across 86 sites in the U.S., Canada, Europe, the UK, and Australia. DBV described VITESSE as the largest treatment intervention study in peanut allergy and thanked investigators, patients, and caregivers for participation.